Quanterix Q4 revenue rises 25%

-0.20% Post

Quanterix Corporation

QTRX

5.01

-0.20%

0.00% Post

Overview

Biomarker detection firm's Q4 revenue rose 25% yr/yr
Company expects cash flow breakeven in 2026
Submitted FDA notification for Alzheimer's blood test

Outlook

Quanterix expects 2026 revenue of $169 to $174 mln
Company anticipates cash flow breakeven in second half of 2026
Quanterix expects to end 2026 with $100 mln in cash and no debt

Result Drivers

PRODUCT REVENUE GROWTH - Q4 revenue increased 25% yr/yr, driven by product revenue growth
COST SAVINGS - Implemented $74 mln of cost savings related to Akoya transaction, with 94% of integration milestones complete

Company press release: ID:nBw5QkcNCa

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Product Revenue		$29.22 mln
Q4 Net Income		-$23.12 mln
Q4 Basic EPS		-$0.49
Q4 Gross Profit		$20.04 mln
Q4 Operating Expenses		$44.79 mln
Q4 Operating Income		-$24.75 mln

Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 4 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."
Wall Street's median 12-month price target for Quanterix Corp is $7.50, about 14.5% above its February 27 closing price of $6.55

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.